Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02797847 | A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects | PHASE1 | COMPLETED | 80 | — | — | Jun 7, 2016 | Jan 12, 2018 | Sep 21, 2018 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| ALN-TTRSC02 | ACTIVE_COMPARATOR | - |
| Sterile normal saline 0.9% for SC administration | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-TTRSC02 | DRUG | Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Calculated volume to match active comparator |
Inclusion Criteria: * Male and female subjects, age 18 to 65 years, inclusive. * Body mass index (BMI) ≥18.0 kg/m2 and ≤30 kg/m2 assessed at Screening. * No clinically significant health concerns, as determined by medical history and physical examination, in the opinion of the Investigator. * Women...